Clinical Trials Using Antibody-Drug Conjugate SC16LD6.5

Clinical trials are research studies that involve people. The clinical trials on this list are studying Antibody-Drug Conjugate SC16LD6.5. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • A Study of ABBV-181 in Participants With Advanced Solid Tumors

    This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax. The study will consist of 3 parts: ABBV-181 monotherapy dose escalation and expansion, ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • A Long-Term Study of Rovalpituzumab Tesirine

    The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
    Location: 2 locations